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ABSTRACT
From October 1999 to September 2006, 29 carba-
penem-resistant isolates of Acinetobacter baumannii
were collected consecutively from patients hospi-
talized in different wards of the University Hos-
pital in Pleven, Bulgaria. The blaOXA-23 gene,
associated with the upstream-located ISAba1,
was identified as the mechanism responsible for
carbapenem resistance in all isolates. The isolates
belonged to two different clonal groups, indicat-
ing a sustained hospital outbreak. This study
demonstrates both the epidemic potential of
carbapenem-resistant A. baumannii and its
longevity in the hospital environment.
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Acinetobacter baumannii is recognized as an impor-
tant hospital-acquired pathogen, particularly in
the intensive care unit (ICU) setting. In many
cases, the carbapenems have become the drugs of
choice for treatment of multidrug-resistant A. bau-
mannii infections. The results from the 2001–2004
SENTRY Antimicrobial Surveillance Program
demonstrate that carbapenem resistance in
A. baumannii has steadily increased and varied
from 11% and 14% for North America and Latin
America, respectively, to 26% for Europe and
Asia [1]. Among the mechanisms of carbapenem
resistance, production of class B and D carbapen-
emases is the most common [2].
The aim of this study was to investigate
the mechanisms of carbapenem resistance in
A. baumannii isolates collected during the period
1999–2006 from the University Hospital in Pleven,
Bulgaria, and to evaluate the clonal relationship
among the isolates.
In total, 29 consecutive carbapenem-resistant
(CR) A. baumannii isolates were obtained from 29
patients hospitalized in different clinical wards of
the hospital, but predominantly in the ICU.
Fifteen randomly chosen carbapenem-susceptible
(CS) A. baumannii isolates collected from 15
patients in eight different hospital wards during
the same period were included for comparison.
Patient data, including age, sex, underlying dis-
ease, hospital unit, and date and site of isolation,
are shown in Table 1. Species identification was
performed by VITEK 2 with GN identification
cards (bioMe´rieux, Marcy l’Etoile, France;
catalogue no. 21341) and confirmed by gyrB
multiplex PCR [3], identification of the intrinsic
blaOXA-51-like gene [4], and amplified ribosomal
DNA restriction analysis [5].
MICs were determined by VITEK 2 AST-N061
cards (bioMe´rieux, catalogue no. 22151). Imipe-
nem MICs were confirmed by use of the agar
dilution method, and the results were interpreted
according to the current CLSI guidelines [6].
For tigecycline, the EUCAST clinical MIC
breakpoints for Enterobacteriaceae (http://www.
srga.org/eucastwt/MICTAB/MICtigecycline.htm)
were used. All CR isolates were resistant to
imipenem as well as to meropenem. The imipe-
nem MICs, determined by the agar dilution
method, varied between 16 and 32 mg ⁄L. The
meropenem MICs obtained by the VITEK 2
instrument also varied within this range. All
isolates exhibited a multidrug-resistant
phenotype characterized by resistance to all
tested b-lactams, aminoglycosides and fluoroqu-
inolones (Table 1). The rate of resistance to tige-
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cycline (MIC ‡4 mg ⁄L) was 72.5%. Only colistin
retained activity against all isolates (data not
shown).
The Etest MBL (AB BIODISK, Solna, Sweden)
suggested that 15 isolates might harbour a metallo-
b-lactamase. However, PCR performed with
primers specific for the genes encoding VIM- and
IMP-type enzymes [7] was negative for all isolates.
Multiplex PCR was used to detect the presence of
blaOXA-23-like, blaOXA-24-like, blaOXA-58-like and
blaOXA-51-like genes [4]. In addition, PCR assays
were performed using primers specific for blaAmpC
and ISAba1 [8,9]. The blaOXA-23-like carbapenemase
gene was found in all CR isolates, amplifying a PCR
product of 501 bp. The intrinsic blaOXA-51-like and
blaAmpC genes [8,10] were also found in all CR and
CS isolates, amplifying PCR products of 353 and
700 bp, respectively. ISAba1 was detected in all CR
isolates. The CS isolates were negative for blaOXA-23-
like, blaOXA-24-like and blaOXA-58-like genes.
The results from PCR mapping, using combi-
nations of ISAba1 primers and the OXA-23-like,
OXA-51-like and AmpC reverse primers [9,11],
showed that ISAba1 was located upstream of the
blaOXA-23-like gene in all isolates, giving a band
of 1.3 kb. These isolates were resistant to both
imipenem and meropenem (MIC, 16–32 mg ⁄L).
In addition, they showed high ceftazidime MICs
(‡64 mg ⁄L). This is probably caused by hyper-
production of the intrinsic AmpC b-lactamase,
because ISAba1 was also found upstream of the
blaAmpC gene, giving a band of 1.6 kb. ISAba1
was not found to be associated with the blaOXA-
51-like gene in any of the isolates. The sequence
analysis confirmed the presence of blaOXA-23.
Electroporation experiments using plasmid
extracts from blaOXA-23-like gene-positive isolates
were unsuccessful in transferring carbapenem
resistance to the electrocompetent A. baumannii
ATCC 19606. In addition, the plasmid extractions
were negative for the blaOXA-23-like gene using
PCR, while genomic DNA preparations were
positive, suggesting that the blaOXA-23-like gene
was chromosomally located.
All A. baumannii isolates were initially geno-
typed by random amplification of polymorphic
DNA (RAPD)-PCR, using M13 primer [12]. The
CR isolates were represented by four RAPD
patterns—a, a1, a2 and b—of which patterns a,
a1 and a2 were closely related. Pattern a and the
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CR isolates (Table 1). Among the 15 CS isolates,
eight different RAPD patterns were discerned.
Pulsed-field gel electrophoresis (PFGE) of the
ApaI-digested genomic DNA [13] of 35 selected
A. baumannii isolates (including all CR and six CS
isolates) confirmed the coexistence of two CR
A. baumannii clones (clone A and clone B), of
which clone A was predominant (Table 1,
Fig. 1). The two clones were clustered in time.
Although the first isolate was recovered in 1999,
clone A was predominant in the ICU from 2003
through 2006. As a single isolate, it was also
recovered in four other hospital wards during the
period 1999–2006. Twenty isolates showed PFGE
pulsotype A. According to the criteria of Tenover
et al. [14], they were considered to represent the
same strain. In addition, five subtypes (A1–A5)
were detected. Subtypes A1, A2 and A3 were
closely related to the isolates with PFGE pattern A,
showing differences of two to three bands (Fig. 1).
Isolates with PFGE subtypes A4 and A5, which
were CS, were considered to be possibly related,
because they differed by four to six bands from
the isolates with pulsotype A. The genetic vari-
ability observed among clone A isolates could be
explained by the long period during which this
clone was present in the hospital (1999–2006), as
well as by the high selective antibiotic pressure,
especially in the ICU setting. Clone B, which also
originated in 1999, dominated between 1999 and
2000 in the ICU, but a single isolate was also
found in April 2006 in a general surgery ward.
The identical PFGE pulsotype B was also found
in three CS isolates, recovered from ICU patients
between December 1999 and September 2000.
Interestingly, CS and CR isolates from both clonal
groups coexisted during the initial phase of the
outbreak, suggesting that the emergence of CR
A. baumannii was probably caused by acquisition
of resistance determinants by a previously sus-
ceptible strain with (clone A) or without (clone B)
minor changes to their respective PFGE patterns.
In conclusion, details of a sustained outbreak
of CR A. baumannii in a Bulgarian university
hospital are presented. Molecular typing re-
vealed that two OXA-23-producing CR A. bau-
mannii clones have spread among several wards
of the hospital during the period 1999–2006,
indicating nosocomial cross-transmission. The
blaOXA-23 gene was identified as the mediator of
the carbapenem resistance. In this respect, our
results reflect the global spread of the OXA-23
group of enzymes among Acinetobacter spp.
[2,15–17]. The data also confirm findings of the
ARPAC study group [18], which recently re-
ported CR A. baumannii isolates harbouring the
OXA-23-like enzyme from various European
countries including Bulgaria; epidemiological
details, however, were not reported.
This study demonstrates both the epidemic
potential of CR A. baumannii and its longevity in
the hospital environment.
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ABSTRACT
The data available in the literature concerning
Cryptococcus gattii in vitro antifungal susceptibility
are contradictory. We have analyzed the activity of
eight antifungal agents against 23 C. gattii clinical
isolates and compared the susceptibility profiles
with those of C. neoformans. MIC analysis (mg ⁄L)
revealed that C. gattii isolates were more suscep-
tible to amphotericin B and flucytosine than were
C. neoformans isolates. Fluconazole and other azole
compounds showed high MIC values for C. gattii.
Posaconazole displayed good activity. Further
studies are required to ascertain the predictive
value of the in vitro data presented here.
Keywords Antifungal susceptibility testing, Crypto-
coccus gattii, emerging yeast, EUCAST method, posa-
conazole
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The Cryptococcus neoformans species complex com-
prises basidiomycetous yeasts that are able to
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